Short Interest in Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Grows By 178.9%

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) was the target of a significant increase in short interest in March. As of March 13th, there was short interest totaling 123,788 shares, an increase of 178.9% from the February 26th total of 44,387 shares. Approximately 0.0% of the company’s stock are sold short. Based on an average daily volume of 1,966,781 shares, the days-to-cover ratio is currently 0.1 days. Based on an average daily volume of 1,966,781 shares, the days-to-cover ratio is currently 0.1 days. Approximately 0.0% of the company’s stock are sold short.

Bayer Aktiengesellschaft Price Performance

Shares of BAYRY opened at $10.90 on Wednesday. The company has a current ratio of 1.14, a quick ratio of 0.71 and a debt-to-equity ratio of 1.10. The company’s fifty day simple moving average is $12.45 and its 200 day simple moving average is $10.18. Bayer Aktiengesellschaft has a 1-year low of $5.30 and a 1-year high of $14.85. The company has a market cap of $42.84 billion, a price-to-earnings ratio of -9.82 and a beta of 0.69.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last announced its quarterly earnings results on Wednesday, March 4th. The company reported $0.18 EPS for the quarter, meeting analysts’ consensus estimates of $0.18. Bayer Aktiengesellschaft had a negative net margin of 8.51% and a positive return on equity of 15.35%. The firm had revenue of $13.24 billion during the quarter, compared to analysts’ expectations of $13.08 billion. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.251-1.400 EPS. On average, research analysts forecast that Bayer Aktiengesellschaft will post 1.31 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the stock. UBS Group upgraded shares of Bayer Aktiengesellschaft from a “neutral” rating to a “buy” rating in a report on Monday, March 16th. Barclays raised shares of Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a research report on Tuesday, January 6th. Zacks Research downgraded shares of Bayer Aktiengesellschaft from a “strong-buy” rating to a “hold” rating in a research note on Monday, February 23rd. Morgan Stanley upgraded Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a report on Wednesday, December 3rd. Finally, JPMorgan Chase & Co. upgraded Bayer Aktiengesellschaft from a “neutral” rating to an “overweight” rating in a report on Monday, December 8th. Two analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy”.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.